Skip to main content
Erschienen in: Current Treatment Options in Cardiovascular Medicine 8/2020

01.08.2020 | Imaging (Q Truong, Section Editor)

Cardiovascular Magnetic Resonance Imaging Tissue Characterization in Non-ischemic Cardiomyopathies

verfasst von: J. Rodriguez-Ortiz, MD, A. Abuzaid, MD, FACP, FASE, FACC, Agbor-Etang Brian, MD, K. Ordovas, MD MAS, FNASCI, FSCMR

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

In this review, we will focus the role of CMR in dilated cardiomyopathy and genetic cardiomyopathy.

Recent findings

Non-invasive imaging plays a crucial rule in the diagnostic workup of cardiomyopathies. In these entities, echocardiography is the first-line imaging tool for diagnostic assessment, but CMR has the unique capability to identify and differentiate the underlying pathology, mainly through tissue characterization, even if the EF is preserved. Myocardial tissue characterization is crucial for adequate prognostication and guiding of therapy. Visual, semi-quantitative, and quantitative methods allow the accurate description of myocardial pathologies such as edema, hyperemia, hypoperfusion, and fibrosis. Basic CMR protocols and standardized post-processing methods are well established and routinely performed.

Summary

CMR has the ability to characterize concomitantly the myocardial tissue characteristics using techniques such as LGE, T1 mapping with ECV measurements, and T2 mapping, and also deformation functional parameters (i.e., strain) and thus provides important insights into the underlying etiology of cardiomyopathy and prognosis. The results of several studies show that CMR findings are associated with clinical outcomes and can inform the management of these patients, including longitudinal assessment of treatment response. CMR should be routinely used in the workup of patients with non-ischemic cardiomyopathy for both diagnostic and prognostic applications.
The presence of LV dilatation and systolic dysfunction in the absence of significant coronary artery disease together with valvular diseases represents a significant etiology to cause cardiomyopathy in cardiology practices. Additionally, other etiologies as infiltrative heart diseases, channelopathy/genetic cardiomyopathy and cardiac involvement in systemic diseases and oncologic process complete the spectrum that may range from isolated LV involvement or biventricular failure. Non-invasive imaging plays a crucial rule in the diagnostic workup of cardiomyopathies. In these entities, echocardiography is the first-line imaging tool for diagnostic assessment, but CMR has the unique capability to identify and differentiate the underlying pathology, mainly through tissue characterization, even if the EF is preserved. Myocardial tissue characterization is crucial for adequate prognostication and guiding of therapy. Visual, semi-quantitative, and quantitative methods allow the accurate description of myocardial pathologies such as edema, hyperaemia, hypoperfusion, and fibrosis. Basic CMR protocols and standardized post-processing methods are well established and routinely performed.
Literatur
1.
Zurück zum Zitat Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99:932–7.PubMedCrossRef Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99:932–7.PubMedCrossRef
2.
Zurück zum Zitat • Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18(1):89 Reader can find these references helpful to understand the role of CMR in different disease process with different and newer CMR applications. • Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016;18(1):89 Reader can find these references helpful to understand the role of CMR in different disease process with different and newer CMR applications.
3.
Zurück zum Zitat Brown PF, Miller C, Di Marco A, et al. Towards cardiac MRI based risk stratification in idiopathic dilated cardiomyopathy. Heart. 2019;105:270–5.PubMedCrossRef Brown PF, Miller C, Di Marco A, et al. Towards cardiac MRI based risk stratification in idiopathic dilated cardiomyopathy. Heart. 2019;105:270–5.PubMedCrossRef
4.
Zurück zum Zitat Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908.PubMedCrossRef Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908.PubMedCrossRef
5.
Zurück zum Zitat Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2015;16:14–22.PubMedCrossRef Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2015;16:14–22.PubMedCrossRef
6.
Zurück zum Zitat Moon JC, Messroghli DR, Kellman P, Piechnik SK, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. JCMR. 2013;15:92. Moon JC, Messroghli DR, Kellman P, Piechnik SK, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. JCMR. 2013;15:92.
7.
Zurück zum Zitat Kammerlander AA, Marzluf BA, Zotter- Tufaro C, et al. T1 mapping by CMR imaging: from histological validation to clinical implication. JACC Card Imag 2016 Jan;9(1):14–23. Kammerlander AA, Marzluf BA, Zotter- Tufaro C, et al. T1 mapping by CMR imaging: from histological validation to clinical implication. JACC Card Imag 2016 Jan;9(1):14–23.
8.
Zurück zum Zitat McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54–9.PubMedCrossRef McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54–9.PubMedCrossRef
9.
Zurück zum Zitat Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardio- myopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; quality of care and outcomes re- search and functional genomics and translation- al biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006;113:1807–16.PubMedCrossRef Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardio- myopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; quality of care and outcomes re- search and functional genomics and translation- al biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006;113:1807–16.PubMedCrossRef
10.
Zurück zum Zitat Shehata ML, Turkbey EB, Vogel-Claussen J, Bluemke DA. Role of cardiac magnetic resonance imaging in assessment of nonischemic cardiomyo- pathies. Top Magn Reson Imaging. 2008;19:43–57.PubMedCrossRef Shehata ML, Turkbey EB, Vogel-Claussen J, Bluemke DA. Role of cardiac magnetic resonance imaging in assessment of nonischemic cardiomyo- pathies. Top Magn Reson Imaging. 2008;19:43–57.PubMedCrossRef
11.
Zurück zum Zitat Ordovas KG, Reddy GP, Higgins CB. MRI in nonischemic acquired heart disease. J Magn Reson Imaging. 2008;27:1195–213.PubMedCrossRef Ordovas KG, Reddy GP, Higgins CB. MRI in nonischemic acquired heart disease. J Magn Reson Imaging. 2008;27:1195–213.PubMedCrossRef
12.
Zurück zum Zitat Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20:421–8.PubMedCrossRef Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20:421–8.PubMedCrossRef
13.
Zurück zum Zitat Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26:1461–74.PubMedCrossRef Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26:1461–74.PubMedCrossRef
14.
Zurück zum Zitat Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverterdefibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011;57:821–8.PubMedCrossRef Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverterdefibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011;57:821–8.PubMedCrossRef
15.
Zurück zum Zitat Pedretti S, Vargiu S, Baroni M, Dellegrottaglie S, Lanzarin B, Roghi A, et al. Complexity of scar and ventricular arrhythmias in dilated cardiomyopathy of any etiology: long-term data from the SCARFEAR (Cardiovascular Magnetic Resonance Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy Delivery) Registry. Clin Cardiol. 2018;41(4):494–501.PubMedPubMedCentralCrossRef Pedretti S, Vargiu S, Baroni M, Dellegrottaglie S, Lanzarin B, Roghi A, et al. Complexity of scar and ventricular arrhythmias in dilated cardiomyopathy of any etiology: long-term data from the SCARFEAR (Cardiovascular Magnetic Resonance Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy Delivery) Registry. Clin Cardiol. 2018;41(4):494–501.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–30.PubMedCrossRef Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–30.PubMedCrossRef
17.
Zurück zum Zitat Barison A, Aimo A, Castiglione V, Arzilli C, et al. Late gadolinium enhancement predicts appropriate defibrillator interventions in noni- schaemic dilated cardiomyopathy. European Heart Journal - Cardiovascular Imaging. 2019;20(Issue Supplement 2):jez102.002.CrossRef Barison A, Aimo A, Castiglione V, Arzilli C, et al. Late gadolinium enhancement predicts appropriate defibrillator interventions in noni- schaemic dilated cardiomyopathy. European Heart Journal - Cardiovascular Imaging. 2019;20(Issue Supplement 2):jez102.002.CrossRef
18.
Zurück zum Zitat Leong DP, Chakrabarty A, Shipp N, Molaee P, Madsen PL, Joerg L, et al. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in newpresentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J. 2012;33:640–8.PubMedCrossRef Leong DP, Chakrabarty A, Shipp N, Molaee P, Madsen PL, Joerg L, et al. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in newpresentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J. 2012;33:640–8.PubMedCrossRef
19.
Zurück zum Zitat Pi SH, Kim SM, Choi JO, Kim EK, Chang SA, Choe YH, et al. Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction. J Cardiovasc Magn Reson. 2018;20(1):36.PubMedPubMedCentralCrossRef Pi SH, Kim SM, Choi JO, Kim EK, Chang SA, Choe YH, et al. Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction. J Cardiovasc Magn Reson. 2018;20(1):36.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Klem I, Weinsaft JW, Bahnson TD, Hegland D, Kim HW, Hayes B, et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol. 2012;60:408–20.PubMedPubMedCentralCrossRef Klem I, Weinsaft JW, Bahnson TD, Hegland D, Kim HW, Hayes B, et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol. 2012;60:408–20.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Barison A, Aimo A, Castiglione V, Arzilli C, et al. Late gadolinium enhancement predicts appropriate defibrillator interventions in noni- ischemic dilated cardiomyopathy. European Heart Journal - Cardiovascular Imaging. 2019;20(Issue Supplement 2):jez102.002.CrossRef Barison A, Aimo A, Castiglione V, Arzilli C, et al. Late gadolinium enhancement predicts appropriate defibrillator interventions in noni- ischemic dilated cardiomyopathy. European Heart Journal - Cardiovascular Imaging. 2019;20(Issue Supplement 2):jez102.002.CrossRef
22.
Zurück zum Zitat •Pontone G, Guaricci AI, Andreini D, et al. Prognostic benefit of cardiac magnetic resonance over transthoracic echocardiography for the assessment of ischemic and nonischemic dilated cardiomyopathy patients referred for the evaluation of primary prevention implantable cardioverter-defibrillator therapy. Circ Cardiovasc Imaging. 2016;9(10) Reader can find these references helpful to understand the role of CMR in different disease process with different and newer CMR applications. •Pontone G, Guaricci AI, Andreini D, et al. Prognostic benefit of cardiac magnetic resonance over transthoracic echocardiography for the assessment of ischemic and nonischemic dilated cardiomyopathy patients referred for the evaluation of primary prevention implantable cardioverter-defibrillator therapy. Circ Cardiovasc Imaging. 2016;9(10) Reader can find these references helpful to understand the role of CMR in different disease process with different and newer CMR applications.
23.
Zurück zum Zitat Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:29.PubMedPubMedCentralCrossRef Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:29.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Sandeep P, Andrew J, Taylor B, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction. The CAMERA-MRI Study. JACC. 2017;70(16):1950–61. Sandeep P, Andrew J, Taylor B, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction. The CAMERA-MRI Study. JACC. 2017;70(16):1950–61.
25.
Zurück zum Zitat Siontis KC, Kim HM, Sharaf Dabbagh G, Latchamsetty R, Stojanovska J, Jongnarangsin K, et al. Association of preprocedural cardiac magnetic resonance imaging with outcomes of ventricular tachycardia ablation in patients with idiopathic dilated cardiomyopathy. Heart Rhythm. 2017 Oct;14(10):1487–93. Siontis KC, Kim HM, Sharaf Dabbagh G, Latchamsetty R, Stojanovska J, Jongnarangsin K, et al. Association of preprocedural cardiac magnetic resonance imaging with outcomes of ventricular tachycardia ablation in patients with idiopathic dilated cardiomyopathy. Heart Rhythm. 2017 Oct;14(10):1487–93.
26.
Zurück zum Zitat Youn JC, Yj H, Lee HJ, Lee HJ, et al. Contrast-enhanced T1 mapping based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective a cohort study. Eur Radiol. 2017;27(9):3924–33.PubMedCrossRef Youn JC, Yj H, Lee HJ, Lee HJ, et al. Contrast-enhanced T1 mapping based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective a cohort study. Eur Radiol. 2017;27(9):3924–33.PubMedCrossRef
27.
Zurück zum Zitat Zhuang B, Sirajuddin A, Wang S, et al. Prognostic value of T1 mapping and extracellular volume fraction in cardiovascular disease: a systematic review and meta-analysis. Heart rEV. 2018;23(5):723–31. Zhuang B, Sirajuddin A, Wang S, et al. Prognostic value of T1 mapping and extracellular volume fraction in cardiovascular disease: a systematic review and meta-analysis. Heart rEV. 2018;23(5):723–31.
28.
Zurück zum Zitat Chen R, Wang J, Du Z, Juan YH, Chan CW, Fei H, et al. The comparison of short-term prognostic value of T1 mapping with feature tracking by cardiovascular magnetic resonance in patients with severe dilated cardiomyopathy. Int J Cardiovasc Imaging. 2019;35(1):171–8.PubMedCrossRef Chen R, Wang J, Du Z, Juan YH, Chan CW, Fei H, et al. The comparison of short-term prognostic value of T1 mapping with feature tracking by cardiovascular magnetic resonance in patients with severe dilated cardiomyopathy. Int J Cardiovasc Imaging. 2019;35(1):171–8.PubMedCrossRef
29.
Zurück zum Zitat Inui K, Asai K, Tachi M, et al. Extracellular volume fraction assessed using cardiovascular magnetic resonance can predict improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy. Heart Vessels. 2018;33(10):1195–203.PubMedCrossRef Inui K, Asai K, Tachi M, et al. Extracellular volume fraction assessed using cardiovascular magnetic resonance can predict improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy. Heart Vessels. 2018;33(10):1195–203.PubMedCrossRef
30.
Zurück zum Zitat Spieker M, Katsianos E, Gastl M, Behm P, et al. T2 mapping cardiovascular magnetic resonance identifies the presence of myocardial inflammation in patients with dilated cardiomyopathy as compared to endomyocardial biopsy. Eur Heart J Cardiovascular Imaging. 2018;195(5):574–82.CrossRef Spieker M, Katsianos E, Gastl M, Behm P, et al. T2 mapping cardiovascular magnetic resonance identifies the presence of myocardial inflammation in patients with dilated cardiomyopathy as compared to endomyocardial biopsy. Eur Heart J Cardiovascular Imaging. 2018;195(5):574–82.CrossRef
31.
Zurück zum Zitat Nakamori S, Bui AH, Jang J, el-Rewaidy HA, Kato S, Ngo LH, et al. Increased myocardial native Ti relaxation time in patients with nonischemic dilated cardiomyopathy with complex ventricular arrythmias. J Magn Imaging. 2018;47(3):779–86.CrossRef Nakamori S, Bui AH, Jang J, el-Rewaidy HA, Kato S, Ngo LH, et al. Increased myocardial native Ti relaxation time in patients with nonischemic dilated cardiomyopathy with complex ventricular arrythmias. J Magn Imaging. 2018;47(3):779–86.CrossRef
32.
Zurück zum Zitat Kato S, Nakamori S, Roujol S, Delling FN, Akhtari S, Jang J, et al. Relationship between native papillary muscle T1 time and severity of functional mitral regurgitation in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Magn Reson. 2016;18(1):79.PubMedPubMedCentralCrossRef Kato S, Nakamori S, Roujol S, Delling FN, Akhtari S, Jang J, et al. Relationship between native papillary muscle T1 time and severity of functional mitral regurgitation in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Magn Reson. 2016;18(1):79.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Buss SJ, Breuninger K, Lehrke S, Voss A, Galuschky C, Lossnitzer D, et al. Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2015;16:307–15.PubMedCrossRef Buss SJ, Breuninger K, Lehrke S, Voss A, Galuschky C, Lossnitzer D, et al. Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2015;16:307–15.PubMedCrossRef
34.
Zurück zum Zitat Pan J, Wan Q, Li J, Wu H, Gao C, Tao Y, et al. Strain values of the left ventricular segments reduces non-homogeneosly in dilated cardiomyopathy with moderately and severely deteriorated heart function assessed by MRI tissue tracking imaging. Int Heart J. 2018;59:1312–9.PubMedCrossRef Pan J, Wan Q, Li J, Wu H, Gao C, Tao Y, et al. Strain values of the left ventricular segments reduces non-homogeneosly in dilated cardiomyopathy with moderately and severely deteriorated heart function assessed by MRI tissue tracking imaging. Int Heart J. 2018;59:1312–9.PubMedCrossRef
35.
Zurück zum Zitat Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–54.PubMedCrossRef Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–54.PubMedCrossRef
36.
Zurück zum Zitat Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. J Am Coll Cardiol. 2004;44:1164–71.PubMedCrossRef Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. J Am Coll Cardiol. 2004;44:1164–71.PubMedCrossRef
37.
Zurück zum Zitat Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52:559–66.PubMedCrossRef Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52:559–66.PubMedCrossRef
38.
Zurück zum Zitat Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112:855–61.PubMedCrossRef Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112:855–61.PubMedCrossRef
39.
Zurück zum Zitat Kwon DH, Setser RM, Popovic ZB, et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging. 2008;24:617–25.PubMedCrossRef Kwon DH, Setser RM, Popovic ZB, et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging. 2008;24:617–25.PubMedCrossRef
40.
Zurück zum Zitat Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369–74.PubMedCrossRef Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369–74.PubMedCrossRef
41.
Zurück zum Zitat Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:51–8.PubMedCrossRef Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:51–8.PubMedCrossRef
42.
Zurück zum Zitat O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867–74.PubMedCrossRef O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867–74.PubMedCrossRef
43.
Zurück zum Zitat Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875–87.PubMedCrossRef Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875–87.PubMedCrossRef
44.
Zurück zum Zitat Avegliano G, Politi MT, Costabel JP, Kuschnir P, Trivi M, Ronderos R. Differences in the extent of fibrosis in obstructive and nonobstructive hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2019 Jun;20(6):389–96. Avegliano G, Politi MT, Costabel JP, Kuschnir P, Trivi M, Ronderos R. Differences in the extent of fibrosis in obstructive and nonobstructive hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2019 Jun;20(6):389–96.
45.
Zurück zum Zitat Raman B, Ariga R, Spartera M, Sivalokanathan S, Chan K, Dass S, et al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications. Eur Heart J Cardiovasc Imaging. 2019;20(2):157–67.PubMedCrossRef Raman B, Ariga R, Spartera M, Sivalokanathan S, Chan K, Dass S, et al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications. Eur Heart J Cardiovasc Imaging. 2019;20(2):157–67.PubMedCrossRef
46.
Zurück zum Zitat Hinojar R, Fernández-Golfín C, González-Gómez A, Rincón LM, Plaza-Martin M, Casas E, et al. Prognostic implications of global myocardial mechanics in hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking. Relations to left ventricular hypertrophy and fibrosis. Int J Cardiol. 2017;249:467–72.PubMedCrossRef Hinojar R, Fernández-Golfín C, González-Gómez A, Rincón LM, Plaza-Martin M, Casas E, et al. Prognostic implications of global myocardial mechanics in hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking. Relations to left ventricular hypertrophy and fibrosis. Int J Cardiol. 2017;249:467–72.PubMedCrossRef
47.
Zurück zum Zitat Sanaani A, Fuisz A. Cardiac magnetic resonance for diagnosis and risk stratification. Cardiol Clin. 2019;37(1):27–33.PubMedCrossRef Sanaani A, Fuisz A. Cardiac magnetic resonance for diagnosis and risk stratification. Cardiol Clin. 2019;37(1):27–33.PubMedCrossRef
48.
Zurück zum Zitat Ismail TF, Jabbour A, Gulati A, Mallorie A, Raza S, Cowling TE, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart. 2014;100:1851–8.PubMedCrossRef Ismail TF, Jabbour A, Gulati A, Mallorie A, Raza S, Cowling TE, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart. 2014;100:1851–8.PubMedCrossRef
49.
Zurück zum Zitat Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. J Am Coll Cardiol Img. 2016;9:1392–402.CrossRef Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. J Am Coll Cardiol Img. 2016;9:1392–402.CrossRef
50.
Zurück zum Zitat Patel AR, Kramer CM. Role of the cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. J Am Coll Cardiol: Imaging. 2017;10:1180–93.CrossRef Patel AR, Kramer CM. Role of the cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. J Am Coll Cardiol: Imaging. 2017;10:1180–93.CrossRef
51.
Zurück zum Zitat Arbustini E, Di Toro A, Giuliani L, et al. Cardiac phenotypes in hereditary muscle disorders. J Am Coll. 2018;72:2485–506.CrossRef Arbustini E, Di Toro A, Giuliani L, et al. Cardiac phenotypes in hereditary muscle disorders. J Am Coll. 2018;72:2485–506.CrossRef
52.
Zurück zum Zitat Amano Y, Suzuki Y, Yanagisawa F, Omori Y, Matsumoto N. Relationship between extension or texture features of late gadolinium enhancement and ventricular tachyarrhythmias in hypertrophic cardiomyopathy. Biomed Res Int. 2018;2018:4092469.PubMedPubMedCentralCrossRef Amano Y, Suzuki Y, Yanagisawa F, Omori Y, Matsumoto N. Relationship between extension or texture features of late gadolinium enhancement and ventricular tachyarrhythmias in hypertrophic cardiomyopathy. Biomed Res Int. 2018;2018:4092469.PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Cochet H, Morlon L, Vergé MP, Salel M, Camaioni C, Reynaud A, et al. Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy. Arch Cardiovasc Dis. 2018;111(10):591–600.PubMedCrossRef Cochet H, Morlon L, Vergé MP, Salel M, Camaioni C, Reynaud A, et al. Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy. Arch Cardiovasc Dis. 2018;111(10):591–600.PubMedCrossRef
54.
Zurück zum Zitat Cheng S, Fang M, Cui C, Chen X, Yin G, Prasad SK, et al. LGE-CMR-derived texture features reflect poor prognosis in hypertrophic cardiomyopathy patients with systolic dysfunction: preliminary results. Eur Radiol. 2018;28(11):4615–24.PubMedCrossRef Cheng S, Fang M, Cui C, Chen X, Yin G, Prasad SK, et al. LGE-CMR-derived texture features reflect poor prognosis in hypertrophic cardiomyopathy patients with systolic dysfunction: preliminary results. Eur Radiol. 2018;28(11):4615–24.PubMedCrossRef
55.
Zurück zum Zitat Swoboda PP, McDiarmid AK, Erhayiem B, Law GR, et al. Effect of cellular and extracellular pathology assessed by T1 mapping on regional contractile function in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2017;19(1):16.PubMedPubMedCentralCrossRef Swoboda PP, McDiarmid AK, Erhayiem B, Law GR, et al. Effect of cellular and extracellular pathology assessed by T1 mapping on regional contractile function in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2017;19(1):16.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Hinojar R, Varma N, Child N, et al. T1 Mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the International T1 Multicenter Cardiovascular Magnetic Resonance Study. Circ Cardiovasc Imaging. 2015;8:e003285.PubMedCrossRef Hinojar R, Varma N, Child N, et al. T1 Mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the International T1 Multicenter Cardiovascular Magnetic Resonance Study. Circ Cardiovasc Imaging. 2015;8:e003285.PubMedCrossRef
57.
Zurück zum Zitat McLellan A, Ellims AH, Prabhu S, et al. Diffuse ventricular fibrosis on cardiac magnetic resonance imaging associates with ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2016;27:571–80.PubMedCrossRef McLellan A, Ellims AH, Prabhu S, et al. Diffuse ventricular fibrosis on cardiac magnetic resonance imaging associates with ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2016;27:571–80.PubMedCrossRef
58.
Zurück zum Zitat Avanesov M, Münch J, Weinrich J, Well L, Säring D, Stehning C, et al. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. Eur Radiol. 2017;27(12):5136–45.PubMedCrossRef Avanesov M, Münch J, Weinrich J, Well L, Säring D, Stehning C, et al. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. Eur Radiol. 2017;27(12):5136–45.PubMedCrossRef
59.
Zurück zum Zitat Gommans DHF, Cramer GE, Bakker J, Dieker HJ, Michels M, Fouraux MA, et al. High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2018;34(1):113–20.PubMedCrossRef Gommans DHF, Cramer GE, Bakker J, Dieker HJ, Michels M, Fouraux MA, et al. High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2018;34(1):113–20.PubMedCrossRef
60.
Zurück zum Zitat Authors/Task Force Members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. Authors/Task Force Members. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.CrossRef Authors/Task Force Members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. Authors/Task Force Members. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.CrossRef
61.
Zurück zum Zitat Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomy- opathy (from the Italian Registry for hypertrophic cardiomyopathy). Am J Cardiol. 2006;98:960–5.PubMedCrossRef Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomy- opathy (from the Italian Registry for hypertrophic cardiomyopathy). Am J Cardiol. 2006;98:960–5.PubMedCrossRef
62.
Zurück zum Zitat Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111:2033–41.PubMedCrossRef Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111:2033–41.PubMedCrossRef
63.
Zurück zum Zitat Williams LK, et al. Effect of left ventricular outflow tract obstruction on left atrial mechanics in hypertrophic cardiomyopathy. Biomed Res Int. 2015;2015:481245.PubMedPubMedCentralCrossRef Williams LK, et al. Effect of left ventricular outflow tract obstruction on left atrial mechanics in hypertrophic cardiomyopathy. Biomed Res Int. 2015;2015:481245.PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Hage FG, Karakus G, Luke WD Jr, et al. Effect of alcohol-induced septal ablation on left atrial volume and ejection fraction assessed by real time three-dimensional transthoracic echocardiography in patients with hypertrophic cardiomyopathy. Echocardiography. 2008;25(7):784–9.PubMedCrossRef Hage FG, Karakus G, Luke WD Jr, et al. Effect of alcohol-induced septal ablation on left atrial volume and ejection fraction assessed by real time three-dimensional transthoracic echocardiography in patients with hypertrophic cardiomyopathy. Echocardiography. 2008;25(7):784–9.PubMedCrossRef
65.
Zurück zum Zitat Girasis C, Vassilikos V, Efthimiadis GK, Papadopoulou SL, Dakos G, Dalamaga EG, et al. Patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation: advanced echocardiographic evaluation of the left atrium combined with non-invasive P-wave analysis. Eur Heart J Cardiovasc Imaging. 2013;14(5):425–34.PubMedCrossRef Girasis C, Vassilikos V, Efthimiadis GK, Papadopoulou SL, Dakos G, Dalamaga EG, et al. Patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation: advanced echocardiographic evaluation of the left atrium combined with non-invasive P-wave analysis. Eur Heart J Cardiovasc Imaging. 2013;14(5):425–34.PubMedCrossRef
66.
Zurück zum Zitat Debonnaire P, Joyce E, Hiemstra Y, Mertens BJ, Atsma DE, Schalij MJ, et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol. 2017. Debonnaire P, Joyce E, Hiemstra Y, Mertens BJ, Atsma DE, Schalij MJ, et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol. 2017.
67.
Zurück zum Zitat Leng S, Tan RS, Zhao X, Allen JC, Koh AS, Zhong L. Validation of a rapid semi-automated method to assess left atrial longitudinal phasic strains on cine cardiovascular magnetic resonance imaging. J Cardiovasc Magn Reson. 2018;20(1):71.PubMedPubMedCentralCrossRef Leng S, Tan RS, Zhao X, Allen JC, Koh AS, Zhong L. Validation of a rapid semi-automated method to assess left atrial longitudinal phasic strains on cine cardiovascular magnetic resonance imaging. J Cardiovasc Magn Reson. 2018;20(1):71.PubMedPubMedCentralCrossRef
68.
Zurück zum Zitat Hinojar R, Zamorano JL, Fernández-Méndez M, Esteban A, Plaza-Martin M, González-Gómez A, et al. Prognostic value of left atrial function by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2019;35:1055–65.PubMedCrossRef Hinojar R, Zamorano JL, Fernández-Méndez M, Esteban A, Plaza-Martin M, González-Gómez A, et al. Prognostic value of left atrial function by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2019;35:1055–65.PubMedCrossRef
69.
Zurück zum Zitat Farhad H, Seidelmann SB, Vigneault D, Abbasi SA, Yang E, Day SM, et al. Left atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. J Cardiovasc Magn Reson. 2017 Dec 28;19(1):107. Farhad H, Seidelmann SB, Vigneault D, Abbasi SA, Yang E, Day SM, et al. Left atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. J Cardiovasc Magn Reson. 2017 Dec 28;19(1):107.
70.
Zurück zum Zitat Jenni R, Oechslin EN, van der Loo B. Isolated ventricular non-compaction of the myocardium in adults. Heart. 2007;93:11–5.PubMedCrossRef Jenni R, Oechslin EN, van der Loo B. Isolated ventricular non-compaction of the myocardium in adults. Heart. 2007;93:11–5.PubMedCrossRef
71.
Zurück zum Zitat Samsa LA, Yang B, Liu J. Embryonic cardiac chamber maturation: trabeculation, conduction and cardiomyocyte proliferation. Am J Med Genet C Semin Med Genet. 2013;163c:157–68.PubMedCrossRef Samsa LA, Yang B, Liu J. Embryonic cardiac chamber maturation: trabeculation, conduction and cardiomyocyte proliferation. Am J Med Genet C Semin Med Genet. 2013;163c:157–68.PubMedCrossRef
72.
Zurück zum Zitat Gati S, Chandra N, Bennett RL, Reed M, Kervio G, Panoulas VF, et al. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes? Heart. 2013;99:401–8.PubMedCrossRef Gati S, Chandra N, Bennett RL, Reed M, Kervio G, Panoulas VF, et al. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non-compaction in athletes? Heart. 2013;99:401–8.PubMedCrossRef
73.
Zurück zum Zitat Kawel N, Nacif M, Arai AE, Gomes AS, Hundley WG, Johnson WC, et al. Trabeculated (noncompacted) and compact myocardium in adults: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging. 2012;5:357–66.PubMedPubMedCentralCrossRef Kawel N, Nacif M, Arai AE, Gomes AS, Hundley WG, Johnson WC, et al. Trabeculated (noncompacted) and compact myocardium in adults: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging. 2012;5:357–66.PubMedPubMedCentralCrossRef
74.
Zurück zum Zitat Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46:101–5.PubMedCrossRef Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46:101–5.PubMedCrossRef
75.
Zurück zum Zitat Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J. 2010;31:1098–104.PubMedCrossRef Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY, et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J. 2010;31:1098–104.PubMedCrossRef
76.
Zurück zum Zitat Andre F, Burger A, et al. References values for the left and right ventricular trabeculation and non-compacted myocardium. Int J Cardiol. 2015;185:240–7.PubMedCrossRef Andre F, Burger A, et al. References values for the left and right ventricular trabeculation and non-compacted myocardium. Int J Cardiol. 2015;185:240–7.PubMedCrossRef
77.
Zurück zum Zitat Captur G, Muthurangu V, Cook C, Flett AS, Wilson R, Barison A, et al. Quantification of left ventricular trabeculae using fractal analysis. J Cardiovasc Magn Reson. 2013;15:36.PubMedPubMedCentralCrossRef Captur G, Muthurangu V, Cook C, Flett AS, Wilson R, Barison A, et al. Quantification of left ventricular trabeculae using fractal analysis. J Cardiovasc Magn Reson. 2013;15:36.PubMedPubMedCentralCrossRef
78.
Zurück zum Zitat Dellegrottaglie S, Pedrotti P, Roghi A, Pedretti S, Chiariello M, Perrone-Filardi P. Regional and global ventricular systolic function in isolated ventricular non-compaction: pathophysiological insights from magnetic resonance imaging. Int J Cardiol. 2012;158:394–9.PubMedCrossRef Dellegrottaglie S, Pedrotti P, Roghi A, Pedretti S, Chiariello M, Perrone-Filardi P. Regional and global ventricular systolic function in isolated ventricular non-compaction: pathophysiological insights from magnetic resonance imaging. Int J Cardiol. 2012;158:394–9.PubMedCrossRef
79.
Zurück zum Zitat Nucifora G, Aquaro GD, Pingitore A, Masci PG, Lombardi M. Myocardial fibrosis in isolated left ventricular non-compaction and its relation to disease severity. Eur J Heart Fail. 2011;13:170–6.PubMedCrossRef Nucifora G, Aquaro GD, Pingitore A, Masci PG, Lombardi M. Myocardial fibrosis in isolated left ventricular non-compaction and its relation to disease severity. Eur J Heart Fail. 2011;13:170–6.PubMedCrossRef
80.
Zurück zum Zitat Boban M, Pesa V, Gabric ID, Manola S, Persic V, Antic-Kauzlaric H, et al. Auxiliary diagnostic potential of ventricle geometry and late gadolinium enhancement in left ventricular non-compaction; non-randomized case control study. BMC Cardiovasc Disord. 2017 Dec 6;17(1):286. Boban M, Pesa V, Gabric ID, Manola S, Persic V, Antic-Kauzlaric H, et al. Auxiliary diagnostic potential of ventricle geometry and late gadolinium enhancement in left ventricular non-compaction; non-randomized case control study. BMC Cardiovasc Disord. 2017 Dec 6;17(1):286.
81.
Zurück zum Zitat Andreini D, Pontone G, Bogaert J, Roghi A, Barison A, Schwitter J, et al. Long-term prognostic value of cardiac magnetic resonance in left ventricle noncompaction: a prospective multicenter study. J Am Coll Cardiol. 2016;68:2166–8.PubMedCrossRef Andreini D, Pontone G, Bogaert J, Roghi A, Barison A, Schwitter J, et al. Long-term prognostic value of cardiac magnetic resonance in left ventricle noncompaction: a prospective multicenter study. J Am Coll Cardiol. 2016;68:2166–8.PubMedCrossRef
82.
Zurück zum Zitat Mathis S, Tazir M, Magy L, Duval F, le Masson G, Duchesne M, et al. History and current difficulties in classifying inherited myopathies and muscular dystrophies. J Neurol Sci. 2018;384:50–4.PubMedCrossRef Mathis S, Tazir M, Magy L, Duval F, le Masson G, Duchesne M, et al. History and current difficulties in classifying inherited myopathies and muscular dystrophies. J Neurol Sci. 2018;384:50–4.PubMedCrossRef
83.
Zurück zum Zitat Malfatti E, Romero NB. Diseases of the skeletal muscle. Handb Clin Neurol. 2017:429–51. Malfatti E, Romero NB. Diseases of the skeletal muscle. Handb Clin Neurol. 2017:429–51.
84.
Zurück zum Zitat Ashford MW Jr, Liu W, Lin SJ, Abraszewski P, Caruthers SD, Connolly AM, et al. Occult cardiac contractile dysfunction in dystrophin deficient children revealed by cardiac magnetic resonance strain imaging. Circulation. 2005;112:2462–7.PubMedCrossRef Ashford MW Jr, Liu W, Lin SJ, Abraszewski P, Caruthers SD, Connolly AM, et al. Occult cardiac contractile dysfunction in dystrophin deficient children revealed by cardiac magnetic resonance strain imaging. Circulation. 2005;112:2462–7.PubMedCrossRef
85.
Zurück zum Zitat Becker S, Florian A, Patrascu A, Rösch S, Waltenberger J, Sechtem U, et al. Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach. J Cardiovasc Magn Reson. 2016;18:25.PubMedPubMedCentralCrossRef Becker S, Florian A, Patrascu A, Rösch S, Waltenberger J, Sechtem U, et al. Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach. J Cardiovasc Magn Reson. 2016;18:25.PubMedPubMedCentralCrossRef
86.
Zurück zum Zitat Tandon A, Villa CR, Hor KN, et al. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy. J Am Heart Assoc. 2015;4:e001338.PubMedPubMedCentralCrossRef Tandon A, Villa CR, Hor KN, et al. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy. J Am Heart Assoc. 2015;4:e001338.PubMedPubMedCentralCrossRef
87.
Zurück zum Zitat Hor KN, Taylor MD, Al-Khalidi HR, et al. Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function. J Cardiovasc Magn Reson. 2013;15:107.PubMedPubMedCentralCrossRef Hor KN, Taylor MD, Al-Khalidi HR, et al. Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function. J Cardiovasc Magn Reson. 2013;15:107.PubMedPubMedCentralCrossRef
88.
Zurück zum Zitat Panovský R, Pešl M, Holeček T, Máchal J, Feitová V, Mrázová L, et al. Cardiac profile of the Czech population of Duchenne muscular dystrophy patients: a cardiovascular magnetic resonance study with T1 mapping. Orphanet J Rare Dis. 2019;14(1):10.PubMedPubMedCentralCrossRef Panovský R, Pešl M, Holeček T, Máchal J, Feitová V, Mrázová L, et al. Cardiac profile of the Czech population of Duchenne muscular dystrophy patients: a cardiovascular magnetic resonance study with T1 mapping. Orphanet J Rare Dis. 2019;14(1):10.PubMedPubMedCentralCrossRef
89.
Zurück zum Zitat Starc JJ, Moore RA, Rattan MS, Villa CR, Gao Z, Mazur W, et al. Elevated myocardial extracellular volume fraction in Duchenne muscular dystrophy. Pediatr Cardiol. 2017;38(7):1485–92.PubMedCrossRef Starc JJ, Moore RA, Rattan MS, Villa CR, Gao Z, Mazur W, et al. Elevated myocardial extracellular volume fraction in Duchenne muscular dystrophy. Pediatr Cardiol. 2017;38(7):1485–92.PubMedCrossRef
90.
Zurück zum Zitat Soslow JH, Damon SM, Crum K, Lawson MA, et al. Increased myocardial native T1 and extracellular volume in patients with Duchenne muscular dystrophy. J Cardiovasc Magn Reson. 2016;18:5.PubMedPubMedCentralCrossRef Soslow JH, Damon SM, Crum K, Lawson MA, et al. Increased myocardial native T1 and extracellular volume in patients with Duchenne muscular dystrophy. J Cardiovasc Magn Reson. 2016;18:5.PubMedPubMedCentralCrossRef
91.
Zurück zum Zitat Olivieri LJ, Kellman P, McCarter RJ, Cross RR, Hansen MS, Spurney CF. Native T1 values identify myocardial changes and stratify disease severity in patients with Duchenne muscular dystrophy. J Cardiovasc Magn Reson. 2016;18(1):72.PubMedPubMedCentralCrossRef Olivieri LJ, Kellman P, McCarter RJ, Cross RR, Hansen MS, Spurney CF. Native T1 values identify myocardial changes and stratify disease severity in patients with Duchenne muscular dystrophy. J Cardiovasc Magn Reson. 2016;18(1):72.PubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Siegel B, Olivieri L, Gordish-Dressman H, Spurney CF, et al. Myocardial strain using cardiac MR feature tracking and speckle tracking echocardiography in Duchenne muscular dystrophy patients. Pediatr Cardiol. 2018;39(3):478–83.PubMedCrossRef Siegel B, Olivieri L, Gordish-Dressman H, Spurney CF, et al. Myocardial strain using cardiac MR feature tracking and speckle tracking echocardiography in Duchenne muscular dystrophy patients. Pediatr Cardiol. 2018;39(3):478–83.PubMedCrossRef
93.
Zurück zum Zitat Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J. 2010;31:806–14.PubMedPubMedCentralCrossRef Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J. 2010;31:806–14.PubMedPubMedCentralCrossRef
94.
Zurück zum Zitat Pieroni M, Dello Russo A, Marzo F, et al. High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy differential diagnosis by electroanatomic mapping-guided endomyocardial biopsy. J Am Coll Cardiol. 2009;53:681–9.PubMedCrossRef Pieroni M, Dello Russo A, Marzo F, et al. High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy differential diagnosis by electroanatomic mapping-guided endomyocardial biopsy. J Am Coll Cardiol. 2009;53:681–9.PubMedCrossRef
95.
Zurück zum Zitat Fontaine GH, Andreoletti L, Redheuil A. Genetics of myocarditis in cardiomyopathies. Heart Rhythm. 2015;12:774–5.PubMedCrossRef Fontaine GH, Andreoletti L, Redheuil A. Genetics of myocarditis in cardiomyopathies. Heart Rhythm. 2015;12:774–5.PubMedCrossRef
96.
Zurück zum Zitat Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2015;12:766–73.PubMedCrossRef Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2015;12:766–73.PubMedCrossRef
97.
Zurück zum Zitat Ott P, Marcus FI, Sobonya RE, Morady F, Knight BP, Fuenzalida CE. Cardiac sarcoidosis masquerading as right ventricular dysplasia. Pacing Clin Electrophysiol. 2003;26:1498–503.PubMedCrossRef Ott P, Marcus FI, Sobonya RE, Morady F, Knight BP, Fuenzalida CE. Cardiac sarcoidosis masquerading as right ventricular dysplasia. Pacing Clin Electrophysiol. 2003;26:1498–503.PubMedCrossRef
98.
Zurück zum Zitat Kumar S, Baldinger SH, Kapur S, Romero J, Mehta NK, Mahida S, et al. Right ventricular scar-related ventricular tachycardia in nonischemic cardiomyopathy: electrophysiological characteristics, mapping, and ablation of underlying heart disease. J Cardiovasc Electrophysiol. 2018;29:79–89.PubMedCrossRef Kumar S, Baldinger SH, Kapur S, Romero J, Mehta NK, Mahida S, et al. Right ventricular scar-related ventricular tachycardia in nonischemic cardiomyopathy: electrophysiological characteristics, mapping, and ablation of underlying heart disease. J Cardiovasc Electrophysiol. 2018;29:79–89.PubMedCrossRef
99.
Zurück zum Zitat Deac M, Alpendurada F, Fanaie F, Vimal R, Carpenter JP, Dawson A, et al. Prognostic value of cardiovascular magnetic resonance in patients with suspected arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol. 2013;168:3514–21.PubMedCrossRef Deac M, Alpendurada F, Fanaie F, Vimal R, Carpenter JP, Dawson A, et al. Prognostic value of cardiovascular magnetic resonance in patients with suspected arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol. 2013;168:3514–21.PubMedCrossRef
100.
Zurück zum Zitat Kellman P, Hernando D, Shah S, Zuehlsdorff S, Jerecic R, Mancini C, et al. Multiecho Dixon fat and water separation method for detecting fibro-fatty infiltration in the myocardium. Magn Reson Med. 2009;61:215–21.PubMedPubMedCentralCrossRef Kellman P, Hernando D, Shah S, Zuehlsdorff S, Jerecic R, Mancini C, et al. Multiecho Dixon fat and water separation method for detecting fibro-fatty infiltration in the myocardium. Magn Reson Med. 2009;61:215–21.PubMedPubMedCentralCrossRef
101.
Zurück zum Zitat Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45:98–103.PubMedCrossRef Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45:98–103.PubMedCrossRef
102.
Zurück zum Zitat Xie S, Desjardins B, Kubala M, Liang J, Yang J, van der Geest R, et al. Association of regional epicardial right ventricular electrogram voltage amplitude and late gadolinium enhancement distribution on cardiac magnetic resonance in patients with arrhythmogenic right ventricular cardiomyopathy: implications for ventricular tachycardia ablation. Heart Rhythm. 2018;15(7):987–93.PubMedPubMedCentralCrossRef Xie S, Desjardins B, Kubala M, Liang J, Yang J, van der Geest R, et al. Association of regional epicardial right ventricular electrogram voltage amplitude and late gadolinium enhancement distribution on cardiac magnetic resonance in patients with arrhythmogenic right ventricular cardiomyopathy: implications for ventricular tachycardia ablation. Heart Rhythm. 2018;15(7):987–93.PubMedPubMedCentralCrossRef
103.
Zurück zum Zitat Åström Aneq M, Maret E, Brudin L, Svensson A, Engvall J. Right ventricular systolic function and mechanical dispersion identify patients with arrhythmogenic right ventricular cardiomyopathy. Clin Physiol Funct Imaging. 2018;38(5):779–87.PubMedCrossRef Åström Aneq M, Maret E, Brudin L, Svensson A, Engvall J. Right ventricular systolic function and mechanical dispersion identify patients with arrhythmogenic right ventricular cardiomyopathy. Clin Physiol Funct Imaging. 2018;38(5):779–87.PubMedCrossRef
104.
Zurück zum Zitat Prati G, Vitrella G, Allocca G, et al. Right ventricular strain and dyssynchrony assessment in arrhythmogenic right ventricular cardiomyopathy: cardiac magnetic resonance feature-tracking study. Circ Cardiovasc Imaging. 2015;8:e003647 discussion e003647. Prati G, Vitrella G, Allocca G, et al. Right ventricular strain and dyssynchrony assessment in arrhythmogenic right ventricular cardiomyopathy: cardiac magnetic resonance feature-tracking study. Circ Cardiovasc Imaging. 2015;8:e003647 discussion e003647.
105.
Zurück zum Zitat Bourfiss M, Vigneault DM, Aliyari Ghasebeh M, Murray B, James CA, Tichnell C, et al. Feature tracking CMR reveals abnormal strain in preclinical arrhythmogenic right ventricular dysplasia/ cardiomyopathy: a multisoftware feasibility and clinical implementation study. J Cardiovasc Magn Reson. 2017;19(1):66.PubMedPubMedCentralCrossRef Bourfiss M, Vigneault DM, Aliyari Ghasebeh M, Murray B, James CA, Tichnell C, et al. Feature tracking CMR reveals abnormal strain in preclinical arrhythmogenic right ventricular dysplasia/ cardiomyopathy: a multisoftware feasibility and clinical implementation study. J Cardiovasc Magn Reson. 2017;19(1):66.PubMedPubMedCentralCrossRef
106.
Zurück zum Zitat Lamy J, Soulat G, Evin M, Huber A, de Cesare A, Giron A, et al. Scan-rescan reproducibility of ventricular and atrial MRI feature tracking strain. Comput Biol Med. 2018;92:197–203.PubMedCrossRef Lamy J, Soulat G, Evin M, Huber A, de Cesare A, Giron A, et al. Scan-rescan reproducibility of ventricular and atrial MRI feature tracking strain. Comput Biol Med. 2018;92:197–203.PubMedCrossRef
107.
Zurück zum Zitat Heermann P, Hedderich DM, Paul M, Schülke C, Kroeger JR, Baeßler B, et al. Biventricular myocardial strain analysis in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) using cardiovascular magneticresonance feature tracking. J Cardiovasc Magn Reson. 2014;16:75.PubMedPubMedCentralCrossRef Heermann P, Hedderich DM, Paul M, Schülke C, Kroeger JR, Baeßler B, et al. Biventricular myocardial strain analysis in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) using cardiovascular magneticresonance feature tracking. J Cardiovasc Magn Reson. 2014;16:75.PubMedPubMedCentralCrossRef
108.
Zurück zum Zitat Czimbalmos C, Csecs I, Dohy Z, Toth A, Suhai FI, Müssigbrodt A, et al. Cardiac magnetic resonance based deformation imaging: role of feature tracking in athletes with suspected arrhythmogenic right ventricular cardiomyopathy. Int J Cardiovasc Imaging. 2019;35(3):529–38.PubMedCrossRef Czimbalmos C, Csecs I, Dohy Z, Toth A, Suhai FI, Müssigbrodt A, et al. Cardiac magnetic resonance based deformation imaging: role of feature tracking in athletes with suspected arrhythmogenic right ventricular cardiomyopathy. Int J Cardiovasc Imaging. 2019;35(3):529–38.PubMedCrossRef
109.
Zurück zum Zitat McLeod K, Wall S, Leren IS, Saberniak J, Haugaa KH. Ventricular structure in ARVC: going beyond volumes as a measure of risk. J Cardiovasc Magn Reson. 2016;18(1):73.PubMedPubMedCentralCrossRef McLeod K, Wall S, Leren IS, Saberniak J, Haugaa KH. Ventricular structure in ARVC: going beyond volumes as a measure of risk. J Cardiovasc Magn Reson. 2016;18(1):73.PubMedPubMedCentralCrossRef
110.
Zurück zum Zitat Te Riele AS, Tandri H, Bluemke DA. Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update. J Cardiovasc Magn Reson. 2014;16:50.CrossRef Te Riele AS, Tandri H, Bluemke DA. Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update. J Cardiovasc Magn Reson. 2014;16:50.CrossRef
Metadaten
Titel
Cardiovascular Magnetic Resonance Imaging Tissue Characterization in Non-ischemic Cardiomyopathies
verfasst von
J. Rodriguez-Ortiz, MD
A. Abuzaid, MD, FACP, FASE, FACC
Agbor-Etang Brian, MD
K. Ordovas, MD MAS, FNASCI, FSCMR
Publikationsdatum
01.08.2020
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 8/2020
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-020-00813-1

Weitere Artikel der Ausgabe 8/2020

Current Treatment Options in Cardiovascular Medicine 8/2020 Zur Ausgabe

Cerebrovascular Disease and Stroke (S Silverman, Section Editor)

Infectious Vasculitides of the Central Nervous System

Cerebrovascular Disease and Stroke (S Silverman, Section Editor)

Inflammatory Vasculitides of the Central Nervous System

State-of-the-Arts Informatics (C Stultz, Section Editor)

Deep Learning for Cardiovascular Risk Stratification

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.